All the news Showing 10 of 122 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources People with HIV are at risk for liver fibrosis and steatosis Michael Carter / 21 August 2017 Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ... Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... Nivolumab increases survival for people with advanced liver cancer Liz Highleyman / 22 April 2017 The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well tolerated as a treatment for advanced liver cancer that did not respond to standard treatment, researchers reported on ... NASH: It's Fibrosis, Not Fat, that Matters MedPage Today Gastroenterology / 21 April 2017 Nivolumab produces durable responses & long-term survival in severe liver cancer patients Eurekalert Inf Dis / 21 April 2017 Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies Liz Highleyman / 21 April 2017 People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher ... Antibiotic prophylaxis reduces the risk of short-term death in people with decompensated cirrhosis Keith Alcorn / 20 April 2017 Long-term prophylaxis with the antibiotic norfloxacin significantly reduced the incidence of deaths in people with decompensated cirrhosis over a six-month follow-up period, a French randomised trial reported today at the International Liver Congress ... Statins reduce risk of decompensation for people with HCV- and HBV-related cirrhosis Michael Carter / 18 April 2017 Treatment with statins reduces the risk of decompensated liver disease for people with cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), investigators from Taiwan report in the online edition ... Co-infection with HCV increases cancer risk for people with HIV Michael Carter / 28 March 2017 People with HIV and hepatitis C virus (HCV) co-infection have an increased risk of non-AIDS-defining cancers compared to people with HIV mono-infection, investigators from Spain report in the online edition of AIDS. Even ... ← Prev1...34567...13Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive